Nov 7 (Reuters) - Valeant Pharmaceuticals International Inc (NYSE:VRX) VRX.TO
* Valeant announces third-quarter 2017 results
* Q3 revenue $2.219 billion versus I/B/E/S view $2.15 billion
* Sees FY 2017 revenue $8.65 billion to $8.8 billion
* Q3 GAAP earnings per share $3.69
* Q3 earnings per share view $0.88 -- Thomson Reuters I/B/E/S
* Valeant - Updates 2017 full-year revenue and maintains adjusted EBITDA (non-GAAP) guidance range despite asset divestitures
* Valeant - As of Nov. 7, 2017, reduced total debt by approximately $6 billion since end of Q1 of 2016
* Valeant - Expect to complete sale of Obagi medical products business before end of year & will use net proceeds to pay down senior secured term loans
* Valeant - Exceeded $5 billion commitment to pay down debt from divestiture proceeds, free cash flow earlier than previously stated timing of feb 2018
* FY2017 revenue view $8.66 billion -- Thomson Reuters I/B/E/S
* Valeant - Qtrly adjusted net income of $367 million